PRNewsWire
18 Nov 2025, 16:00 UTC · 42w ago
Verdict
Headline leans bullish. We score INSM +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
The European Commission has approved BRINSUPRI (brensocatib) as the first and only treatment for non-cystic fibrosis bronchiectasis in the EU.
More positive than 99% of claims this week
Insmed plans to engage with EU authorities to secure patient access and expects to begin making BRINSUPRI available in early 2026.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 91% of claims this week
Applications for brensocatib are currently under regulatory review in the U.K. and Japan.
More positive than 85% of claims this week
In the Phase 3 ASPEN study, BRINSUPRI 25 mg achieved a 19.4% reduction in the annual rate of exacerbations compared to placebo and significantly slowed lung function decline.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received European Commission approval for BRINSUPRI, becoming the first and only approved treatment for NCFB in the EU.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
4h ago
−36.5%
Price is moving against the score
$125.30 vs $197.40 close before publication (Nov 17) · not market-adjusted
INSM chart →
